Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0TE2D
|
|||
| Drug Name |
PMID29334795-Compound-25
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED WANG, Rong LU, Hongtao
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H23N3O3
|
|||
| Canonical SMILES |
C1CC(C1)N2CCC(CC2)CC3=NC(=NO3)C4=CC5=C(C=C4)OCO5
|
|||
| InChI |
1S/C19H23N3O3/c1-2-15(3-1)22-8-6-13(7-9-22)10-18-20-19(21-25-18)14-4-5-16-17(11-14)24-12-23-16/h4-5,11,13,15H,1-3,6-10,12H2
|
|||
| InChIKey |
ATGQONNRRWKPGJ-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histamine H3 receptor (H3R) | Target Info | Inverse agonist | [1] |
| Target's Patent Info | Histamine H3 receptor (H3R) | Target's Patent Info | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Histamine receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Monoamine Transport | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.